UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number 001-41231
TC BIOPHARM (HOLDINGS) PLC
(Translation of registrant’s name into English)
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
+44 (0) 141 433 7557
(Address of Principal Executive Offices)
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: |
| ☒ Form 20-F | ☐ Form 40-F |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐ |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐ |
On August 7, 2023, TC Biopharm (Holdings) PLC (the “Company”) received notice of conversion into equity of the outstanding amount of its Convertible Loan Note (the ‘Note’). As a result of this conversion, the Company no longer has any convertible notes currently outstanding.
On December 31, 2022, the Company had accounted for the Note as a liability in the amount of $789,214 and, following several phased conversions since then, that liability has now been converted in its entirety into equity.
| -2- |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TC BIOPHARM (HOLDINGS) PLC | ||
| By: | /s/ Martin Thorp | |
| Name: | Martin Thorp | |
| Title: | Chief Financial Officer | |
| Date: August 22, 2023 | ||
| -3- |